

PRESS RELEASE

Eden Biodesign and IntelliHep are to develop a manufacturing process for heparin based therapeutics as potential treatments for diseases ranging from Alzheimer's to inflammation.


Eden Biodesign (Liverpool, UK), a leading provider of development and manufacturing services for new medicines, announced today that it has been selected by IntelliHep (Liverpool, UK), a leading biotechnology company developing heparin based therapeutics, to establish a commercial manufacturing process for their lead product candidate. Heparin based therapies have a range of potential clinical applications including in the treatment of neurodegenerative and inflammatory diseases, and cancer.

Eden Biodesign will use its extensive expertise in drug development and manufacturing to assist IntelliHep in the establishment of a large scale commercial production process for their product candidate. Dr Crawford Brown, CEO of Eden Biodesign commented: "We are delighted to work with IntelliHep on further development of this novel class of therapeutic and to accelerate their progress from research labs to patients. The award of this contract again reflects the depth of expertise in the Eden Biodesign team across a wide range of technologies."

Dr Bill Primrose, CEO of IntelliHep said: "This deal represents a major step forward in our goal of bringing heparin-based therapies to market. The development of a practical manufacturing process is a critical step for the company and we are delighted that we will benefit from the experience and facilities that Eden can offer."

IntelliHep has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project. The project will be executed at the state of the art National Biomanufacturing Centre (NBC), part of the £34.25 million NBC project developed and owned by the NWDA and funded by the NWDA, ERDF and DTI. Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow, commented: "We are pleased that the NBC is able to provide practical help to IntelliHep for the commercialisation of their discoveries."

Ends



For further details please contact:

Johanne Tabern – Tel No: +44 (0)151 728 1750 – email: Johanne.tabern@edenbiodesign.com

Notes to editors:

Eden Biodesign


Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. Eden Biodesign was appointed to operate the NBC by the government following a Europe wide tendering process. For further information please visit www.edenbiodesign.com.

The National Biomanufacturing Centre

The £34.25 million National Biomanufacturing Centre which was officially opened in November 2006, is a Government-funded initiative led by the Northwest Regional Development Agency (NWDA) additionally funded through the European Regional Development Fund and the Department of Trade and Industry and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.

The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences, delivering the skilled workforce required to expand the UK biopharmaceutical sector.



There is also an Access Fund of nearly £3 million funded by the Department of Trade and Industry and the European Regional Development Fund, which is available to qualifying small-to-medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre.

IntelliHep

IntelliHep is a glycotherapeutics company originating from the world leading research of Professor Jeremy Turnbull, Dr Ed Yates and Dr Andrew Powell, in the School of Biological Sciences at the University of Liverpool. The company has a proprietary technology platform which can generate a diverse array of saccharides from heparin - an “intelligent heparin library”.

Heparin is the world’s largest selling pharmaceutical by weight and has been used in the clinic to prevent blood clotting for over 60 years. It has many other useful biological functions which are exploitable in many therapeutic areas. The remarkable structural diversity of heparin needs to be managed in order for its multiple activities to be exploited in new drug leads, and for unwanted side effects to be eliminated.

IntelliHep is using its technology to advance its in-house research in the field of neurodegeneration, principally Alzheimer’s disease, and is also offering the technology to partners for the discovery and development of new saccharide therapeutics in a range of other medical conditions. For further information please visit www.intellihep.com.